The ATLAS trial presented at #ASCO22
-Given design (3 drugs maint, and PFS as endpoint), answer was obvious.
-Low power to detect any survival difference
-No quality of life presented, suspect would be worse if properly measured in KRd arm
-Please don’t adopt in practice! #mmsm
-Given design (3 drugs maint, and PFS as endpoint), answer was obvious.
-Low power to detect any survival difference
-No quality of life presented, suspect would be worse if properly measured in KRd arm
-Please don’t adopt in practice! #mmsm
Other thoughts:
-induction suboptimal by US standards, suspect benefit would be even less if len was given. Remember- that len based consolidation helps if induction regimen did not contain len (emn02-h095), but does NOT help if induction regimen contains len (STAMINA trial)
-induction suboptimal by US standards, suspect benefit would be even less if len was given. Remember- that len based consolidation helps if induction regimen did not contain len (emn02-h095), but does NOT help if induction regimen contains len (STAMINA trial)
Presenter described treatment as well tolerated. There was a treatment related death in KRd arm. After randomization, 5 patient in len arm withdrew due to “patient decision/other” but 16 withdrew in KRd arm.
That’s informative censoring.And likely because KRd was tough to handle
That’s informative censoring.And likely because KRd was tough to handle
You can see in here- the censoring going on, much more drop outs in KRd arm.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
